Skip to content

Abstract 14492: Comparative Cardiovascular Outcomes of SGLT2 Inhibitors versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major cardiovascular, renal, and diabetes-related complications. Methods: Using the TriNetX Research network (109 healthcare organizations), we identified 728,124 patients initiating SGLT2i and 473,812 initiating DPP4i, all with T2DM and aged ≥18 years, excluding those with type 1 diabetes. Propensity score matching (1:1) balanced cohorts to 300,614 patients each. Index date was the first prescription of the respective drug class. Outcomes were assessed from 1 day to 1,825 days (5 years) post-index. Risks, risk ratios, hazard ratios (HR), and survival probabilities were evaluated using risk analysis, Kaplan-Meier, and number-of-instances methods, with exclusion of patients having the outcome prior to the time window. Results: After matching, SGLT2i use was associated with lower risk of several key outcomes compared to DPP4i. All-cause mortality was markedly reduced (7.1% vs 12.4%; risk ratio 0.570, 95% CI 0.561-0.579; HR 0.519, 95% CI 0.510-0.528; log-rank p<0.001), with 5-year survival of 88.90% vs 79.50%.Cardiovascular benefits included lower cerebral infarction (3.2% vs 3.7%; risk ratio 0.858, 95% CI 0.834-0.882; HR 0.783, 95% CI 0.761-0.806), heart failure (7.4% vs 7.6%; risk ratio 0.969, 95% CI 0.951-0.989; HR 0.857, 95% CI 0.839-0.874), and cardiac arrest (1.0% vs 1.4%; risk ratio 0.671, 95% CI 0.640-0.703; HR 0.616, 95% CI 0.587-0.646). Myocardial infarction risk was similar (3.6% vs 3.5%; risk ratio 1.022, p=0.114), though survival analysis favored SGLT2i (HR 0.928).Renal outcomes showed lower acute kidney injury (AKI) with SGLT2i (8.4% vs 9.9%; risk ratio 0.853, 95% CI 0.839-0.868; HR 0.768) and a modest reduction in chronic kidney disease (CKD) progression (11.8% vs 12.1%; risk ratio 0.976; HR 0.872). Diabetic polyneuropathy (6.3% vs 5.3%; risk ratio 1.178) and ophthalmic complications (5.4% vs 4.5%; risk ratio 1.205) were higher with SGLT2i, while diabetic foot events were marginally increased (2.1% vs 2.0%; risk ratio 1.048). Number of event instances was generally lower or comparable with SGLT2i across most outcomes. Conclusions: In this large propensity score-matched real-world cohort of patients with T2DM, SGLT2i initiation was associated with substantially lower all-cause mortality, reduced cardiovascular events (particularly stroke, heart failure, and cardiac arrest), and better renal outcomes compared to DPP4i over 5 years, supporting the preferential use of SGLT2i in appropriate patients.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.